Drug Type Small molecule drug |
Synonyms Ertugliflozin l-pyroglutamic acid/Metformin Hydrochloride, Ertugliflozin/metformin, MK 8835/metformin + [2] |
Target |
Mechanism PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (19 Dec 2017), |
Regulation- |
Molecular FormulaC4H12ClN5 |
InChIKeyOETHQSJEHLVLGH-UHFFFAOYSA-N |
CAS Registry1115-70-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | US | 19 Dec 2017 |